Stock listing

NASDAQ:RADX Radiopharm Theranostics Limited Stock

US listing (NASDAQ) of Radiopharm Theranostics Limited · home listing ASX:RAD

Follow Radiopharm Theranostics Limited into a list and get an email when it puts out news.

Share price · NASDAQ:RADX

$1.03 USD -0.05 (-4.6%)

Close on Oct 16, 2026

Day range
$0.90 – $1.14 USDOct 16, 2026
Volume
106,391 sharesOct 16, 2026
Market value
$15.03M USDAt the close on Oct 16, 2026 · price × 14.59M shares outstanding
Radiopharm Theranostics Limited logo
Ticker
NASDAQ:RADX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101

Oct 5, 2026

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

Sep 14, 2026

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

Sep 9, 2026

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

Aug 26, 2026

RAD Doses First Patient in Second Cohort of BetaBart (RV-01)

Aug 25, 2026

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

Aug 20, 2026

RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial

Aug 19, 2026

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

Aug 17, 2026

RAD to meet with US FDA to align on RAD 101 Phase 3 Trial

Aug 16, 2026

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up to Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

Jul 27, 2026

All Radiopharm Theranostics Limited news

Financings

  • Registered direct offering of american Depositary Shares with unregistered warrants

    Jul 27, 2026

    Announced: about US$4.1M · US$3.16 a share · Warrants at US$3.79 · H.C. Wainwright & Co.

    Dealers: H.C. Wainwright & Co. (lead)

    Use of proceeds: RAD101 registrational study, advancing therapeutic programs, strategic partnering, working capital and general corporate purposes

    Announced Jul 24, 2026 · Announced Jul 27, 2026

  • Private placement of ordinary shares with attaching options

    Jul 27, 2026 · US$4.68M

    Announced: about A$6.7M · Warrants at A$0.018

    Use of proceeds: RAD101 registrational study, advancing therapeutic programs, strategic partnering, working capital and general corporate purposes

    Announced Jul 24, 2026 · Announced Jul 27, 2026

  • Share purchase plan of ordinary shares with attaching options

    Jul 27, 2026 · US$4.2M

    Announced: up to A$6M · Warrants at A$0.018

    Use of proceeds: RAD101 registrational study, advancing therapeutic programs, strategic partnering, working capital and general corporate purposes

    Announced Jul 24, 2026 · Announced Jul 27, 2026

Read by 6ix AI from the company's releases

Decks

Radiopharm Theranostics Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
49 in the last 12 months · 129 in all · newest Oct 5, 2026 · oldest 2021
Decks
25 decks · latest Jul 24, 2026

Where Radiopharm Theranostics Limited is listed

ListingExchangeCountryCurrency
ASX:RAD · Home listingASXAustraliaAUD
NASDAQ:RADX · This pageNASDAQUnited StatesUSD
OTC:RDPTFOTCUnited StatesUSD
BOATS:RADXBOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about Radiopharm Theranostics Limited.